- Home
- JRVR vs GLSI Comparison
JRVR vs GLSI Comparison
Compare JRVR & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRVR | GLSI |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 244.7M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | JRVR | GLSI |
|---|---|---|
| Price | $4.09 | $15.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $7.33 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 225.9K | 119.2K |
| Earning Date | 05-04-2026 | 05-19-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 125.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $687,614,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.76 | $7.78 |
| 52 Week High | $7.20 | $34.10 |
Technical Indicators
Market Signals| Indicator | JRVR | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 46.87 |
| Support Level | $3.82 | $15.76 |
| Resistance Level | $4.30 | $29.89 |
| Average True Range (ATR) | 0.11 | 1.55 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 62.96 | 28.94 |
Price Performance
Historical ComparisonAbout JRVR James River Group Holdings Ltd.
James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.